Format

Send to

Choose Destination
J Endocrinol. 2019 Aug 1. pii: JOE-19-0267.R1. doi: 10.1530/JOE-19-0267. [Epub ahead of print]

Myo-inositol alters 13C-labeled fatty acid metabolism in human placental explants.

Author information

1
O Watkins, Department of Obestetrics and Gynaecology, Yong Loo Lin School of Medicine,, National University of Singapore, Singapore, Singapore.
2
M Islam, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
3
P Selvam, Department of Obestetrics and Gynaecology, Yong Loo Lin School of Medicine,, National University of Singapore, Singapore, Singapore.
4
R Pillai, Department of Obestetrics and Gynaecology, Yong Loo Lin School of Medicine,, National University of Singapore, Singapore, Singapore.
5
A Cazenave-Gassiot, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
6
A Bendt, Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, Singapore, Singapore.
7
N Karnani, Agency for Science, Technology and Research, Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore, Singapore.
8
K Godfrey, MRC Lifecourse Epidemiology Unit and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom of Great Britain and Northern Ireland.
9
R Lewis, MRC Lifecourse Epidemiology Unit and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom of Great Britain and Northern Ireland.
10
M Wenk, Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, Singapore, Singapore.
11
S Chan, Department of Obstetrics and Gynaecology, National University Singapore Yong Loo Lin School of Medicine, Singapore, Singapore.

Abstract

We postulate that myo-inositol, a proposed intervention for gestational-diabetes, affects transplacental lipid supply to the fetus. We investigated the effect of myo-inositol on fatty-acid processing in human placental-explants from uncomplicated pregnancies. Explants were incubated with 13C-labeled palmitic-acid, 13C-oleic-acid and 13C-docosahexaenoic-acid across a range of myo-inositol concentrations for 24 h and 48 h. The incorporation of labeled-fatty-acids into individual lipids was quantified by liquid-chromatography-mass-spectrometry. At 24 h, myo-inositol increased the amount of 13C-palmitic-acid and 13C-oleic-acid labeled lipids (median fold-change relative to control=1). Significant effects were seen with 30 µM myo-inositol (physiological) for 13C-palmitic-acid-lysophosphatidylcholines (1.26) and 13C-palmitic-acid-phosphatidylethanolamines (1.17). At 48 h, myo-inositol addition increased 13C-oleic-acid-lipids but decreased 13C-palmitic-acid and 13C-docosahexaenoic-acid lipids. Significant effects were seen with 30 µM myo-inositol for 13C-oleic-acid-phosphatidylcholines (1.25), 13C-oleic-acid-phosphatidylethanolamines (1.37) and 13C-oleic-acid-triacylglycerols (1.32) and with 100 µM myo-inositol for 13C-docosahexaenoic-acid-triacylglycerols (0.78). Lipids labeled with the same 13C-fatty-acid showed similar responses when tested at the same time-point, suggesting myo-inositol alters upstream processes such as fatty-acid uptake or activation. Myo-inositol supplementation may alter placental lipid physiology with unknown clinical consequences.

PMID:
31404911
DOI:
10.1530/JOE-19-0267

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center